<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(2)</volume><submitter>Eriksson LB</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>In most cases, a combination of paracetamol and ibuprofen are the optimal treatment for postoperative pain in third molar surgery. If stronger analgesia is required, opioids are traditionally administered. In day-case, surgery; however, opioids should be avoided. Thus, the anaesthetic agent S-ketamine in analgesic doses might be preferred.&lt;h4>Methods&lt;/h4>The study was designed as a randomized placebo-controlled double-blind clinical trial. The study enrolled healthy subjects according to the American Society of Anaesthesiologists classification; I or II (ASA), aged 18 to 44 years, with a body weight between 50 and 100 kg. The patients were randomized into three groups where two doses of S-ketamine were compared (high: 0.25 mg/kg or low: 0.125 mg/kg) with placebo (saline).&lt;h4>Results&lt;/h4>A primary outcome of the study was that VAS at 4 h postoperatively, showed no significant difference between the placebo and high-dose S-ketamine group or in the low-dose group. We found a significant difference between the groups for the first 24 h, with a lower VAS-score in the high-dose S-ketamine group. The time to when 50% had taken their first rescue medication was 12 min later in the high-dose ketamine group.&lt;h4>Conclusions&lt;/h4>Pre-emptive S-ketamine 0.25 mg/kg gave a global significant reduction of pain by VAS during the first 24 h postoperatively. The time from end of surgery to first rescue medication were longer in the high-dose ketamine group compared to both low-dose ketamine and placebo groups.</pubmed_abstract><journal>British journal of pain</journal><pagination>197-208</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10964853</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Intravenous S-ketamine's analgesic efficacy in third molar surgery. A randomized placebo-controlled double-blind clinical trial.</pubmed_title><pmcid>PMC10964853</pmcid><pubmed_authors>Tegelberg A</pubmed_authors><pubmed_authors>Karlsten R</pubmed_authors><pubmed_authors>Eriksson LB</pubmed_authors><pubmed_authors>Gordh T</pubmed_authors><pubmed_authors>Thor A</pubmed_authors><pubmed_authors>LoMartire R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intravenous S-ketamine's analgesic efficacy in third molar surgery. A randomized placebo-controlled double-blind clinical trial.</name><description>&lt;h4>Background&lt;/h4>In most cases, a combination of paracetamol and ibuprofen are the optimal treatment for postoperative pain in third molar surgery. If stronger analgesia is required, opioids are traditionally administered. In day-case, surgery; however, opioids should be avoided. Thus, the anaesthetic agent S-ketamine in analgesic doses might be preferred.&lt;h4>Methods&lt;/h4>The study was designed as a randomized placebo-controlled double-blind clinical trial. The study enrolled healthy subjects according to the American Society of Anaesthesiologists classification; I or II (ASA), aged 18 to 44 years, with a body weight between 50 and 100 kg. The patients were randomized into three groups where two doses of S-ketamine were compared (high: 0.25 mg/kg or low: 0.125 mg/kg) with placebo (saline).&lt;h4>Results&lt;/h4>A primary outcome of the study was that VAS at 4 h postoperatively, showed no significant difference between the placebo and high-dose S-ketamine group or in the low-dose group. We found a significant difference between the groups for the first 24 h, with a lower VAS-score in the high-dose S-ketamine group. The time to when 50% had taken their first rescue medication was 12 min later in the high-dose ketamine group.&lt;h4>Conclusions&lt;/h4>Pre-emptive S-ketamine 0.25 mg/kg gave a global significant reduction of pain by VAS during the first 24 h postoperatively. The time from end of surgery to first rescue medication were longer in the high-dose ketamine group compared to both low-dose ketamine and placebo groups.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2025-04-04T19:11:31.102Z</modification><creation>2025-04-04T19:11:31.102Z</creation></dates><accession>S-EPMC10964853</accession><cross_references><pubmed>38545499</pubmed><doi>10.1177/20494637231222327</doi></cross_references></HashMap>